Reduced Cardiovascular and Renal Events with Canaglifozin (CANVAS + CANVAS-R)
EBM, Journal Club
Thank you, Alex, for a review of outcome data for one of the newest diabetes medications: canaglifozin (Invokana®). Canaglifozin is a SGLT2 inhibitor, which decreases reabsorption of glucose in the renal tubules. Clinical Question: Among patients with DM2 at high risk…